Larotrectinib

DRUG8 trials

Sponsors

Region Hovedstaden, National Cancer Institute (NCI), Nationwide Children's Hospital, Oslo University Hospital, West China Hospital

Conditions

Advanced LymphomaAdvanced Malignant Solid NeoplasmAdvanced pancreatic cancerBladder CarcinomaBreast CarcinomaCervical CarcinomaColon CarcinomaColorectal Carcinoma

Early Phase 1

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

RecruitingNCT04655404

Nationwide Children's HospitalDiffuse Intrinsic Pontine Glioma, High Grade Glioma

Start: 2021-04-08End: 2036-12-01Target: 15Updated: 2026-03-18

Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Active, not recruitingNCT02465060

National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma +49

Start: 2015-08-17End: 2026-12-31Target: 6452Updated: 2026-05-13

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

RecruitingNCT05725200

Oslo University HospitalMetastatic Colorectal Cancer

Start: 2022-09-27End: 2040-12-31Target: 40Updated: 2023-02-21

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

Active, not recruitingNCT06390852

National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma +2

Start: 2017-03-12End: 2026-12-31Target: 35Updated: 2026-05-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

RecruitingNCT06482086

West China HospitalLocally Advanced Thyroid Gland Carcinoma

Start: 2021-06-01End: 2025-12-01Target: 75Updated: 2024-12-05

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

RecruitingNCT06563999

Sun Yat-sen UniversityLung Cancer Stage III, Mutation

Start: 2024-11-01End: 2029-11-01Target: 120Updated: 2026-04-21

TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02)

Not yet recruitingCTIS2025-522431-34-00

Region HovedstadenAdvanced pancreatic cancer

Target: 1200Updated: 2026-05-18

Phase 4

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

Not yet recruitingNCT07010393

Fujian Medical UniversityThyroid Neoplasms

Start: 2025-07-01End: 2028-12-31Target: 335Updated: 2025-06-08

Related Papers

Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.

2025-10-09

Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial.

Journal of Clinical Oncology2025-05-281 citations

Precision treatment guided by patient-derived organoids-based drug testing for locally advanced thyroid cancer: a single arm, phase 2 study.

2025-04-303 citations

Molecular profiling of plasma from matched NCI-MATCH gynecological cancers.

Journal of Clinical Oncology2024-06-011 citations

Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial

The Oncologist2024-05-306 citations

Abstract B007: Concordance between tumor tissue and plasma genotyping in NCI-MATCH Trial (EAY131)

Molecular Cancer Therapeutics2023-12-01

Revolutionizing cancer drug development: Harnessing the potential of basket trials.

2023-11-0720 citations

The NCI-MATCH trial: lessons for precision oncology.

2023-06-15103 citations

Phase II study of crizotinib in patients with <i>MET</i> amplification and <i>MET</i> exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.

Journal of Clinical Oncology2023-06-012 citations

Discovery of gene fusions in driver-negative NCI-MATCH screening samples.

Journal of Clinical Oncology2023-06-011 citations

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature Medicine2023-04-14244 citations

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Clinical Cancer Research2023-01-2055 citations

Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology

npj Precision Oncology2022-10-2715 citations

Abstract 2438: Determining the role of non-mutated C-Raf kinase in metastatic disease

Cancer Research2022-06-15

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.

2022-06-077 citations

Phase II study of vismodegib in patients with <i>SM</i>O or <i>PTCH1</i> mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T.

Journal of Clinical Oncology2022-06-013 citations

HGG-24. NTRK-rearranged infantile gliomas of suprasellar/ optic pathway origin

Neuro-Oncology2022-06-01

Molecular predictors of response among patients with MMRd tumors treated on NCI-MATCH Arm Z1D.

Journal of Clinical Oncology2022-06-01

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers

The Oncologist2022-04-1445 citations

Abstract P2-13-24: Distinct HER2 allele specific therapeutic response and preclinical efficacy of poziotinib in metastatic ER+ HER2 mutant breast cancer

Cancer Research2022-02-151 citations

19 more papers not shown